(Q37994555)

26 August 2017

title

Emerging disease-modifying therapies in multiple sclerosis (English)

1 reference

26 August 2017

0 references

1 reference

ChEBI release 2020-05-28

Jai Perumal

1

1 reference

26 August 2017

Omar Khan

series ordinal

2

1 reference

26 August 2017

publication date

1 June 2012

1 reference

Current treatment options in neurology

26 August 2017

published in

1 reference

26 August 2017

volume

14

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

256-263

1 reference

Compliance, adherence, and the treatment of multiple sclerosis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Ocrelizumab: a step forward in the evolution of B-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11940-012-0173-X

NF-kappaB and its regulation on the immune system.

21 January 2018

1 reference

12 December 2020

Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells

1 reference

12 December 2020

The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

10.1007/S11940-012-0173-X

Identifiers

DOI

1 reference

26 August 2017

1 reference